XML 77 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 10 - Commitments and Contingencies (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Mar. 14, 2017
Feb. 02, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Operating Leases, Rent Expense, Net     $ 200 $ 136 $ 33
Research and Development Expenses Settled by Shares Issuance     $ 42,259
Shares Issued, Price Per Share $ 20        
Private Placement [Member] | Nereus Trust [Member]          
Stock Issued in Lieu of Royalty Payments 2,112,963        
Wanchun Biotech [Member]          
Quarterly Royalty Payments Required As a Percentage of Gross Proceeds on Sale of Product     20.00%    
Term of Royalty Payments     10 years    
Wanchun Biotech and Fortis Advisors LLC [Member]          
Period Following Royalty Termination Agreement, Requirement to Issue Shares   3 years      
Percentage of Fully-diluted Equity Capitalization Required to Be Issued As Shares in Lieu of Royalty Payments   10.00%